Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting
- Resource Type
- Authors
- Siddhartha Yadav; Kathryn D. Cook; Aminah Jatoi; Lisa M. Lammert; Yahya Almodallal; Minji Lee; Jennifer Le-Rademacher; Amrit B. Singh
- Source
- Breast Cancer Research and Treatment. 188:15-20
- Subject
- 0301 basic medicine
Cancer Research
medicine.medical_specialty
business.industry
Medical record
Cancer
medicine.disease
Rash
Clinical trial
03 medical and health sciences
Diarrhea
030104 developmental biology
0302 clinical medicine
Breast cancer
Oncology
Older patients
030220 oncology & carcinogenesis
Internal medicine
Medicine
medicine.symptom
Adverse effect
business
- Language
- ISSN
- 1573-7217
0167-6806
Alpelisib is newly-available breast cancer agent that targets PIK3 mutations and confers a somewhat unusual adverse event profile. This study focused on older patients (≥ 65 years of age) treated outside a clinical trial to gain further experience on how these under-studied patients do with this new agent. This descriptive, multi-site study relied on medical record review. Fifty-one older breast cancer patients were started on alpelisib between May 2019 and September 2020. The median age and number of comorbidities at alpelisib initiation was 71 years and 4, respectively. Thirty-five patients had stopped alpelisib (median time on drug 2.6 months (range